| Systematic (IUPAC) name | |
|---|---|
| (8β)- 6-methyl- 8- (morpholin- 4- ylcarbonyl)- 9,10- didehydroergoline | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Pharmacokinetic data | |
| Metabolism | hepatic |
| Excretion | renal |
| Identifiers | |
| CAS number | 4314-63-0 |
| ATC code | ? |
| PubChem | CID 199507 |
| ChemSpider | 172695 |
| Synonyms | LSM-775, N-Morpholinyllysergamide, Lysergic acid morpholide |
| Chemical data | |
| Formula | C20H23N3O2 |
| Mol. mass | 337.43 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
N-Morpholinyllysergamide (LSM-775) is a derivative of ergine. It is reported to have some LSD-like effects at doses ranging from 75 to 700 micrograms. LSM-775 is said to produce dream like states similar to DXM. Its visual component is like that of LSD, but it is said to be less intense and not as pronounced as LSD.